Does the media favor VMD or ACH?

In the previous week, Viemed Healthcare had 7 more articles in the media than Accendra Health. MarketBeat recorded 10 mentions for Viemed Healthcare and 3 mentions for Accendra Health. Viemed Healthcare's average media sentiment score of 1.40 beat Accendra Health's score of 1.29 indicating that Viemed Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viemed Healthcare 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TACO or ACH?

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 22.45%. Given Accendra Health's stronger consensus rating and higher possible upside, analysts clearly believe Accendra Health is more favorable than Berto Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Berto Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable earnings and valuation, TACO or ACH?

Berto Acquisition has higher earnings, but lower revenue than Accendra Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Berto Acquisition N/A N/A N/A N/A N/A Accendra Health $2.73B 0.03 -$1.10B -$3.91 N/A

Does the media refer more to TACO or ACH?

In the previous week, Berto Acquisition had 1 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Berto Acquisition and 3 mentions for Accendra Health. Accendra Health's average media sentiment score of 1.29 beat Berto Acquisition's score of 0.40 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Berto Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Accendra Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACH or BDSX more profitable?

Accendra Health has a net margin of -11.41% compared to Biodesix's net margin of -26.97%. Accendra Health's return on equity of -4.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -11.41% -4.02% 0.70% Biodesix -26.97% -788.19% -30.33%

Does the media refer more to ACH or BDSX?

In the previous week, Accendra Health had 1 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for Biodesix. Accendra Health's average media sentiment score of 1.29 beat Biodesix's score of 0.69 indicating that Accendra Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACH or INFU?

In the previous week, Accendra Health and Accendra Health both had 3 articles in the media. InfuSystem's average media sentiment score of 1.75 beat Accendra Health's score of 1.29 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accendra Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is XGN or ACH more profitable?

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Accendra Health -11.41% -4.02% 0.70%

Does the media prefer XGN or ACH?

In the previous week, Exagen and Exagen both had 3 articles in the media. Accendra Health's average media sentiment score of 1.29 beat Exagen's score of 1.08 indicating that Accendra Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exagen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Accendra Health (ACH) Competitors

$1.23 +0.02 (+1.24%)

As of 08/28/2026 03:58 PM Eastern

Compare

ACH vs. VMD, TACO, BDSX, INFU, and XGN

Should you buy Accendra Health stock or one of its competitors? Accendra Health's main competitors and comparable companies include Viemed Healthcare (VMD), Berto Acquisition (TACO), Biodesix (BDSX), InfuSystem (INFU), and Exagen (XGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Accendra Health compare to Viemed Healthcare?

Viemed Healthcare (NASDAQ:VMD) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Viemed Healthcare had 7 more articles in the media than Accendra Health. MarketBeat recorded 10 mentions for Viemed Healthcare and 3 mentions for Accendra Health. Viemed Healthcare's average media sentiment score of 1.40 beat Accendra Health's score of 1.29 indicating that Viemed Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viemed Healthcare	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viemed Healthcare presently has a consensus target price of $14.00, indicating a potential upside of 58.73%. Accendra Health has a consensus target price of $1.50, indicating a potential upside of 22.45%. Given Viemed Healthcare's stronger consensus rating and higher possible upside, research analysts clearly believe Viemed Healthcare is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Viemed Healthcare has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Viemed Healthcare has a net margin of 4.81% compared to Accendra Health's net margin of -11.41%. Viemed Healthcare's return on equity of 10.16% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	4.81%	10.16%	7.22%
Accendra Health	-11.41%	-4.02%	0.70%

74.2% of Viemed Healthcare shares are held by institutional investors. 20.6% of Viemed Healthcare shares are held by insiders. Comparatively, 2.3% of Accendra Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Viemed Healthcare has higher earnings, but lower revenue than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$270.28M	1.24	$14.93M	$0.36	24.50
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Summary

Viemed Healthcare beats Accendra Health on 14 of the 16 factors compared between the two stocks.

How does Accendra Health compare to Berto Acquisition?

Berto Acquisition (NASDAQ:TACO) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Accendra Health has a consensus target price of $1.50, indicating a potential upside of 22.45%. Given Accendra Health's stronger consensus rating and higher possible upside, analysts clearly believe Accendra Health is more favorable than Berto Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berto Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Berto Acquisition has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Accendra Health has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

Berto Acquisition has a net margin of 0.00% compared to Accendra Health's net margin of -11.41%. Berto Acquisition's return on equity of 0.00% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Berto Acquisition	N/A	N/A	N/A
Accendra Health	-11.41%	-4.02%	0.70%

Berto Acquisition has higher earnings, but lower revenue than Accendra Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berto Acquisition	N/A	N/A	N/A	N/A	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

In the previous week, Berto Acquisition had 1 more articles in the media than Accendra Health. MarketBeat recorded 4 mentions for Berto Acquisition and 3 mentions for Accendra Health. Accendra Health's average media sentiment score of 1.29 beat Berto Acquisition's score of 0.40 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Berto Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Accendra Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Accendra Health beats Berto Acquisition on 6 of the 9 factors compared between the two stocks.

How does Accendra Health compare to Biodesix?

Accendra Health (NYSE:ACH) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Accendra Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Accendra Health presently has a consensus price target of $1.50, suggesting a potential upside of 22.45%. Biodesix has a consensus price target of $31.33, suggesting a potential upside of 16.78%. Given Accendra Health's higher possible upside, analysts clearly believe Accendra Health is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Biodesix has lower revenue, but higher earnings than Accendra Health. Biodesix is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
Biodesix	$88.50M	3.20	-$35.26M	-$3.17	N/A

In the previous week, Accendra Health had 1 more articles in the media than Biodesix. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for Biodesix. Accendra Health's average media sentiment score of 1.29 beat Biodesix's score of 0.69 indicating that Accendra Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Accendra Health has a net margin of -11.41% compared to Biodesix's net margin of -26.97%. Accendra Health's return on equity of -4.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
Biodesix	-26.97%	-788.19%	-30.33%

21.0% of Biodesix shares are held by institutional investors. 2.3% of Accendra Health shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Accendra Health beats Biodesix on 9 of the 17 factors compared between the two stocks.

How does Accendra Health compare to InfuSystem?

Accendra Health (NYSE:ACH) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

InfuSystem has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
InfuSystem	$143.34M	1.70	$870K	$0.41	29.37

In the previous week, Accendra Health and Accendra Health both had 3 articles in the media. InfuSystem's average media sentiment score of 1.75 beat Accendra Health's score of 1.29 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accendra Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has a net margin of 1.12% compared to Accendra Health's net margin of -11.41%. InfuSystem's return on equity of 2.78% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
InfuSystem	1.12%	2.78%	1.41%

Accendra Health has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Accendra Health presently has a consensus target price of $1.50, indicating a potential upside of 22.45%. InfuSystem has a consensus target price of $16.67, indicating a potential upside of 38.43%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts clearly believe InfuSystem is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

71.1% of InfuSystem shares are held by institutional investors. 2.3% of Accendra Health shares are held by insiders. Comparatively, 10.8% of InfuSystem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InfuSystem beats Accendra Health on 13 of the 15 factors compared between the two stocks.

How does Accendra Health compare to Exagen?

Exagen (NASDAQ:XGN) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

In the previous week, Exagen and Exagen both had 3 articles in the media. Accendra Health's average media sentiment score of 1.29 beat Exagen's score of 1.08 indicating that Accendra Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Exagen shares are owned by institutional investors. 10.4% of Exagen shares are owned by insiders. Comparatively, 2.3% of Accendra Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Accendra Health	-11.41%	-4.02%	0.70%

Exagen presently has a consensus target price of $9.63, indicating a potential upside of 30.24%. Accendra Health has a consensus target price of $1.50, indicating a potential upside of 22.45%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Exagen has higher earnings, but lower revenue than Accendra Health. Exagen is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.69	-$19.95M	-$0.81	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Exagen has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Summary

Exagen beats Accendra Health on 10 of the 16 factors compared between the two stocks.

Get Accendra Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACH vs. The Competition

Export

Metric	Accendra Health	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$93.06M	$9.87B	$7.20B	$24.19B
Dividend Yield	N/A	2.56%	2.54%	3.71%
P/E Ratio	-0.31	34.69	273.16	29.99
Price / Sales	0.03	4.91	592.64	19.53
Price / Cash	0.32	120.59	76.74	32.24
Price / Book	-0.17	4.00	12.98	7.67
Net Income	-$1.10B	$312.92M	$3.48B	$1.07B
7 Day Performance	2.08%	-1.34%	0.13%	-0.32%
1 Month Performance	-63.32%	0.93%	7.08%	1.84%
1 Year Performance	N/A	15.34%	24.67%	13.37%

Accendra Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACH Accendra Health	2.6184 of 5 stars	$1.23 +1.2%	$1.50 +22.4%	N/A	$93.06M	$2.73B	N/A	6,500	Positive News
VMD Viemed Healthcare	4.6586 of 5 stars	$9.14 -2.0%	$14.00 +53.2%	+19.7%	$348.12M	$301.61M	25.39	1,382	News Coverage
TACO Berto Acquisition	0.7949 of 5 stars	$10.48 -0.2%	N/A	+1.7%	$341.69M	N/A	N/A	7,892	News Coverage Short Interest Increase
BDSX Biodesix	3.8285 of 5 stars	$29.27 -4.3%	$31.33 +7.0%	+214.5%	$308.83M	$102.94M	N/A	220
INFU InfuSystem	4.0007 of 5 stars	$12.03 -0.1%	$16.67 +38.6%	+11.7%	$242.89M	$143.34M	200.62	410	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ACH) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accendra Health (ACH) Competitors

ACH vs. VMD, TACO, BDSX, INFU, and XGN

How does Accendra Health compare to Viemed Healthcare?

Summary

How does Accendra Health compare to Berto Acquisition?

Summary

How does Accendra Health compare to Biodesix?

Summary

How does Accendra Health compare to InfuSystem?

Summary

How does Accendra Health compare to Exagen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accendra Health (ACH) Competitors

ACH vs. VMD, TACO, BDSX, INFU, and XGN

How does Accendra Health compare to Viemed Healthcare?

Does the media favor VMD or ACH?

Do analysts recommend VMD or ACH?

Which has more risk and volatility, VMD or ACH?

Is VMD or ACH more profitable?

Do institutionals & insiders believe in VMD or ACH?

Which has better valuation & earnings, VMD or ACH?

Summary

How does Accendra Health compare to Berto Acquisition?

Do analysts prefer TACO or ACH?

Which has more risk & volatility, TACO or ACH?

Is TACO or ACH more profitable?

Which has preferable earnings and valuation, TACO or ACH?

Does the media refer more to TACO or ACH?

Summary

How does Accendra Health compare to Biodesix?

Which has more risk & volatility, ACH or BDSX?

Do analysts recommend ACH or BDSX?

Which has higher earnings & valuation, ACH or BDSX?

Does the media refer more to ACH or BDSX?

Is ACH or BDSX more profitable?

Do insiders & institutionals have more ownership in ACH or BDSX?

Summary

How does Accendra Health compare to InfuSystem?

Which has better earnings & valuation, ACH or INFU?

Does the media favor ACH or INFU?

Is ACH or INFU more profitable?

Which has more risk and volatility, ACH or INFU?

Do analysts prefer ACH or INFU?

Do institutionals & insiders believe in ACH or INFU?

Summary

How does Accendra Health compare to Exagen?

Does the media prefer XGN or ACH?

Do insiders and institutionals believe in XGN or ACH?

Is XGN or ACH more profitable?

Do analysts rate XGN or ACH?

Which has better earnings & valuation, XGN or ACH?

Which has more risk & volatility, XGN or ACH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools